Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

ABSTRACT:

Background

Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown.

Methods

Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED). irAEs spectrum in patients treated upfront with ED and association between irAEs and overall survival were also described.

Results

A total of 550 (68%) pati

SUBMITTER: Cantini L 

PROVIDER: S-EPMC10323889 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature